Follow Us:
Diclofenac Ophthalmic

Voltarol

Diclofenac Ophthalmic

Diclofenac Ophthalmic is a non-steroidal anti-inflammatory eye medication used to reduce ocular pain, inflammation, and discomfort following eye surgery or certain inflammatory conditions. It works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin production and the associated inflammatory response. Depending on the specific product and approved indication, it may be prescribed for postoperative inflammation, pain following cataract surgery, or seasonal allergic conjunctivitis. It is commonly available as sterile ophthalmic eye drops. Possible side effects include temporary burning, stinging, eye irritation, and blurred vision. Use requires ophthalmic supervision, as prolonged treatment may delay corneal healing or increase the risk of corneal complications in susceptible patients.

Dosage Form: Eye Drops
Dosage Strength:
CAS No.: 15307-86-5
Status:
Manufacturer:
Group: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Sub Group: Non-selective COX inhibitors
Class: Anthranilic acid derivatives

Uses of Diclofenac Ophthalmic

Diclofenac Ophthalmic was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:

  • Menstrual pain: Mefenamic acid is commonly used for the relief of primary dysmenorrhoea and menstrual cramps.
  • Musculoskeletal pain: Management of pain associated with muscle injuries, sprains, strains, and joint disorders.
  • Rheumatoid arthritis: Certain fenamates, such as meclofenamate, have been used to relieve inflammatory joint symptoms.
  • Osteoarthritis: Relief of pain and inflammation associated with degenerative joint conditions, where an individual medicine is appropriate.
  • Dental pain: Short-term relief of toothache and pain following selected dental procedures.
  • Headaches and migraines: Certain fenamates, particularly tolfenamic acid where available, may be used for acute headache or migraine treatment.
  • Acute inflammatory pain: Management of selected painful inflammatory conditions.

Contraindication of Diclofenac Ophthalmic

Diclofenac Ophthalmic was historically subject to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Known hypersensitivity to the medicine, aspirin, or other NSAIDs.
  • History of serious NSAID-induced asthma, urticaria, or allergic reactions.
  • Active peptic ulcer disease or gastrointestinal bleeding.
  • Severe renal impairment or severe hepatic impairment.
  • Severe heart failure or certain serious cardiovascular conditions.
  • Active pathological bleeding or significant bleeding disorders.
  • Perioperative pain management associated with coronary artery bypass graft (CABG) surgery.
  • Late pregnancy, particularly from 30 weeks onward.

Precautions for Diclofenac Ophthalmic

Diclofenac Ophthalmic was majorly subjected to specific precautions during administration to ensure patient safety. Its former precautions included:

  • Gastrointestinal effects: Fenamates may cause abdominal pain, nausea, diarrhoea, stomach irritation, peptic ulcers, and gastrointestinal bleeding.
  • Kidney function: Use cautiously in patients with kidney impairment, dehydration, or conditions that may reduce renal blood flow.
  • Liver function: Some fenamates may cause elevated liver enzymes or other hepatic complications. Monitoring may be necessary during prolonged treatment.
  • Cardiovascular risk: Patients with hypertension, heart disease, or a history of stroke should use these medicines cautiously.
  • Bleeding risk: Fenamates may affect platelet function and increase bleeding risk, particularly when combined with anticoagulants.
  • Asthma and allergies: Patients with aspirin-sensitive asthma or previous NSAID-related allergic reactions should avoid these medicines unless medically advised.
  • Pregnancy: Avoid routine use from 20 weeks of pregnancy unless specifically advised by a healthcare professional; use from 30 weeks onward is generally avoided.
  • Treatment duration: Use the lowest effective dose for the shortest appropriate period to minimise adverse effects.

Drug Interactions for Diclofenac Ophthalmic

Potential drug interactions were historically documented when Diclofenac Ophthalmic was prescribed alongside certain medications. These included:

  • Anticoagulants: Warfarin and direct oral anticoagulants may increase the risk of gastrointestinal and other bleeding.
  • Antiplatelet medicines: Aspirin and clopidogrel may increase bleeding risk when combined with fenamates.
  • Corticosteroids: Prednisolone and other corticosteroids may increase the risk of gastrointestinal ulcers and bleeding.
  • Other NSAIDs: Concurrent use with ibuprofen, diclofenac, naproxen, or other NSAIDs may increase adverse effects.
  • ACE inhibitors and ARBs: Combination may reduce blood-pressure control and increase the risk of kidney injury.
  • Diuretics: Fenamates may reduce the effectiveness of diuretics and increase the risk of fluid retention and renal impairment.
  • Lithium: NSAIDs may increase lithium concentrations and the risk of toxicity.
  • Methotrexate: Concurrent use may reduce methotrexate clearance and increase the risk of toxicity.
  • Antihypertensive medicines: Fenamates may reduce the effectiveness of certain blood-pressure-lowering treatments.

Frequently Asked Questions

The most frequently asked questions focus on import, export, documentations, and regulation for Diclofenac Ophthalmic.

The Diclofenac is a pharmaceutical active pharmaceutical ingredient (API) used in manufacturing of Diclofenac Ophthalmic.

: Provides active pharmaceutical ingredients (APIs), customized production, and OEM/ODM services with research and technical cooperation across Europe, the USA, and India via Primeera Healthcare.

  • Therapeutic Goods Administration (TGA):
  • US Food and Drug Administration (USFDA):
  • European Medicines Agency (EMA):
  • African Medicines Agency (AMA):
  • National Medical Products Administration (NMPA):
  • Central Drugs Standard Control Organization (CDSCO):

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Diclofenac Ophthalmic, subject to confirmation of its current regulatory status and eligibility for import into India.

Documentation Required for Diclofenac Ophthalmic Import

The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.

Import Regulations and dcoumentation for Diclofenac Ophthalmic

  • Import Documentation Assistance:
    Support with organising commercial invoices, packing lists, manufacturer details, product specifications, certificates of analysis, and other relevant documents required for regulatory review and customs processing.

  • Regulatory Coordination:
    Assistance with identifying applicable CDSCO requirements, import authorisations, and documentation procedures, subject to the product's regulatory status and the proposed import route.
  • Shipping and Customs Coordination:
    Coordination with relevant logistics providers and customs professionals to organise shipment documentation and facilitate clearance where legally permitted.
  • Compliance Verification:
    Preliminary review of available product and shipment documentation to identify potential regulatory gaps before procurement or dispatch. Import arrangements will proceed only after the applicable permissions and restrictions have been verified.

Customs Clearance and Compliance Handling of Diclofenac Ophthalmic Import

Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Diclofenac Ophthalmic, subject to confirmation of its current regulatory status and eligibility for import into India.

Export Regulations and dcoumentation for Diclofenac Ophthalmic

The export of Diclofenac Ophthalmic from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.

Documentation Required for Diclofenac Ophthalmic Emport

  • Export Documentation Assistance:
    Assistance with organising commercial invoices, packing lists, manufacturer details, Diclofenac Ophthalmic specifications, certificates of analysis, and other supporting documents required for Diclofenac Ophthalmic export and customs processing.
  • Regulatory Coordination:
    Support in identifying applicable country specific Diclofenac Ophthalmic export requirements, relevant manufacturing and export authorisations, and destination-country registration or import approval requirements, subject to the Diclofenac Ophthalmic regulatory status.
  • Shipping and Customs Coordination:
    Coordination with logistics providers, freight forwarders, and customs professionals to organise shipping documentation, export declarations, and customs clearance procedures where legally permitted.
  • Compliance Verification:
    Preliminary review of available Diclofenac Ophthalmic documentation, labelling, Diclofenac Ophthalmic manufacturing information, and destination-market requirements to identify potential regulatory gaps before dispatch. Export arrangements will proceed only after the applicable restrictions and authorisations have been verified.

Customs Clearance and Compliance Handling of Diclofenac Ophthalmic Export

Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Diclofenac Ophthalmic, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.

Product Export Support

If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.